Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argent Biopharma ( (AU:RGT) ) has shared an announcement.
Argent Biopharma Limited has applied to the ASX for quotation of 2,557,450 new ordinary fully paid shares. The securities are being issued as consideration for purchase order reimbursement, reflecting a non-cash settlement structure with counterparties.
The new shares, dated 10 February 2026, will expand Argent Biopharma’s quoted capital base on the ASX. This issuance may modestly dilute existing shareholders while enhancing the company’s financial flexibility by conserving cash for operational needs.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
More about Argent Biopharma
Argent Biopharma Limited is an Australia-listed biotechnology company trading under the ASX code RGT. The firm operates in the biopharmaceutical sector, though the filing focuses on its capital markets activities rather than specifying particular drugs, therapies or market segments.
Average Trading Volume: 180,786
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.56M
See more insights into RGT stock on TipRanks’ Stock Analysis page.